VNDA

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.

Wall Street analysts forecast VNDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNDA is 15.50 USD with a low forecast of 11.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Vanda Pharmaceuticals Inc revenue for the last quarter amounts to 56.26M USD, increased 18.06 % YoY.

Vanda Pharmaceuticals Inc. EPS for the last quarter amounts to -0.38 USD, increased 322.22 % YoY.

Vanda Pharmaceuticals Inc (VNDA) has 368 emplpoyees as of December 16 2025.

Today VNDA has the market capitalization of 392.70M USD.